RLYBRallybio Corpvs its industry peers
A metric-by-metric comparison of Rallybio Corp against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLYB본 종목 | $85M#3 | — | 1.7x#3 | 99.2x#3 | 34.9%#3 | 84.5%#1 | -3853.6%#4 | -17.9%#2 | — | — | — | — |
| ERNA | $4M#6 | 0.1x#1 | 0.6x#1 | 6.8x#2 | 755.9%#1 | 68.4%#3 | -1601.2%#3 | -205.3%#6 | -203.6%#1 | — | — | — |
| HRTX | $98M#1 | — | 10.7x#6 | 0.6x#1 | 7.4%#5 | -42.9%#7 | -1.6%#1 | -218.9%#7 | — | — | — | — |
| ALDX | $92M#2 | — | 2.2x#4 | — | — | 39.4%#4 | — | -80.3%#4 | — | — | — | — |
| FBIO | — | 0.8x#2 | — | — | 9.7%#4 | 76.2%#2 | -111.0%#2 | 22.8%#1 | — | — | — | — |
| GANX | $74M#4 | — | 5.3x#5 | 1345.0x#5 | -58.4%#6 | 1.2%#6 | -33908.5%#6 | -143.9%#5 | — | — | 21.3%#1 | — |
| IBIO | $71M#5 | — | 0.9x#2 | 177.6x#4 | 77.8%#2 | 26.2%#5 | -4650.5%#5 | -23.7%#3 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice